HighTower Advisors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

HighTower Advisors’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12	Closed	-$4.2K	–	3723
2022 Q4	$4.2K	Buy	12 +1	+9%	+$11	﹤0.01%	3226
2022 Q3	$4K	Buy	+11	New	+$284	﹤0.01%	3071
2022 Q1	–	Sell	-8	Closed	-$8K	–	3751
2021 Q4	$8K	Sell	8 -392	-98%	-$24.4K	﹤0.01%	3177
2021 Q3	$7K	Buy	+400	New	+$29.3K	﹤0.01%	3049

Other funds holding DMK

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

HighTower Advisors's DMK Position: Q1 2023 in Review

HighTower Advisors sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2023, closing a stake of 819 shares — an estimated $9K sold.

HighTower Advisors first reported a position in DMK in Q2 2014 and held it in 20 quarters. The position peaked at $317K in Q2 2014. 47 funds tracked by Wall St. Rank hold DMK as of Q1 2023.

HighTower Advisors reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2023 after selling out during the quarter.
HighTower Advisors sold 819 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2023, an estimated $9K.
HighTower Advisors first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2014 and held it in 20 quarters.
HighTower Advisors's DMK Pharmaceuticals Corporation Common Stock position peaked at $317K in Q2 2014.
47 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2023.

Based on HighTower Advisors's 13F filing for Q1 2023, filed 12 May 2023.